Immunotherapy: a promising therapy for anaplastic thyroid carcinoma

Gao Rili; Guan Haixia

doi:10.13406/j.cnki.cyxb.003121

您当前的位置：

首页 >

文章列表页 >

Immunotherapy: a promising therapy for anaplastic thyroid carcinoma

The management of thyroid cancer | 更新时间：2025-10-21

- Immunotherapy: a promising therapy for anaplastic thyroid carcinoma
- Journal of Chongqing Medical University Vol. 47, Issue 11, Pages: 1261-1264(2022)
- 作者机构：
  
  广东省人民医院·广东省医学科学院内分泌科，广州 510080
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003121
  CLC： R736.1;R979.5
- Received：21 June 2022，
  
  Published：28 November 2022
- 稿件说明：
移动端阅览
高日丽,关海霞.甲状腺未分化癌的免疫治疗：曙光初现，未来可期[J].重庆医科大学学报,2022,47(11):1261-1264.

Gao Rili,Guan Haixia.Immunotherapy: a promising therapy for anaplastic thyroid carcinoma[J].Journal of Chongqing Medical University,2022,47(11):1261-1264.
高日丽,关海霞.甲状腺未分化癌的免疫治疗：曙光初现，未来可期[J].重庆医科大学学报,2022,47(11):1261-1264. DOI： 10.13406/j.cnki.cyxb.003121.

Gao Rili,Guan Haixia.Immunotherapy: a promising therapy for anaplastic thyroid carcinoma[J].Journal of Chongqing Medical University,2022,47(11):1261-1264. DOI： 10.13406/j.cnki.cyxb.003121.

摘要

甲状腺未分化癌（anaplastic thyroid carcinoma，ATC）是一种罕见但恶性程度极高的肿瘤，目前还没有有效的治疗方法。ATC的免疫微环境研究提示，免疫治疗可能使ATC患者获益。已有一些免疫治疗ATC的相关研究陆续开展。免疫检查点抑制剂（单独或与靶向药物联用）、嵌合抗原受体T细胞（chimeric antigen receptor T cell，CAR-T）免疫疗法和个性化肿瘤疫苗（personalized tumor vaccines，PTV）等有望成为ATC治疗的未来方向。

Abstract

Anaplastic thyroid carcinoma（ATC） is rare but one of the most aggressive human cancers，and there is no effective treatments currently. Studies of immune microenvironment in ATC suggest that immunotherapy may benefit for ATC patients，and some studies about immunotherapy in ATC have been gradually conducted. Immune checkpoint inhibitors（given alone or combined with target agents），chimeric antigen receptor T cell（CAR-T），and personalized tumor vaccines（PTV） were expected to be the future direction of medical therapy for ATC.

关键词

Keywords

references

Sung H ， Ferlay J ， Siegel RL ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

Maniakas A ， Dadu R ， Busaidy NL ， et al . Evaluation of overall survival in patients with anaplastic thyroid carcinoma，2000-2019 [J ] . JAMA Oncol ， 2020 ， 6 （ 9 ）： 1397 - 1404 .

French JD . Immunotherapy for advanced thyroid cancers—rationale，current advances and future strategies [J ] . Nat Rev Endocrinol ， 2020 ， 16 （ 11 ）： 629 - 641 .

Ulisse S ， Tuccilli C ， Sorrenti S ， et al . PD-1 ligand expression in epithelial thyroid cancers：potential clinical implications [J ] . Int J Mol Sci ， 2019 ， 20 （ 6 ）： 1405 .

Wherry EJ ， Kurachi M . Molecular and cellular insights into T cell exhaustion [J ] . Nat Rev Immunol ， 2015 ， 15 （ 8 ）： 486 - 499 .

Yu XB ， Gao RL ， Li YQ ， et al . Regulation of PD-1 in T cells for cancer immunotherapy [J ] . Eur J Pharmacol ， 2020 ， 881 ： 173240 .

Diesendruck Y ， Benhar I . Novel immune check point inhibiting antibodies in cancer therapy—opportunities and challenges [J ] . Drug Resist Updat ， 2017 ， 30 ： 39 - 47 .

Kollipara R ， Schneider B ， Radovich M ， et al . Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer [J ] . Oncologist ， 2017 ， 22 （ 10 ）： 1149 - 1151 .

Capdevila J ， Wirth LJ ， Ernst T ， et al . PD-1 blockade in anaplastic thyroid carcinoma [J ] . J Clin Oncol ， 2020 ， 38 （ 23 ）： 2620 - 2627 .

Dierks C ， Seufert J ， Aumann K ， et al . Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma [J ] . Thyroid ， 2021 ， 31 （ 7 ）： 1076 - 1085 .

Christine D , Juri R , Jochen S , et al . Lenvatinib/ Pembrolizumab in metastasized anaplastic thyroid carcinoma (ATC): interim results of the atlep trial [J ] . Thyroid ， 2021 ， 31 （ S1 ）: P-1-A-114.

Cabanillas ME ， Dadu R ， Ferrarotto R ， et al . Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma（ATC） [J ] . J Clin Oncol ， 2020 ， 38 （ 15 Suppl ）： 6514 .

Das S ， Johnson DB . Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors [J ] . J Immunother Cancer ， 2019 ， 7 （ 1 ）： 306 .

Bagchi S ， Yuan R ， Engleman EG . Immune checkpoint inhibitors for the treatment of cancer：clinical impact and mechanisms of response and resistance [J ] . Annu Rev Pathol ， 2021 ， 16 ： 223 - 249 .

Postow MA ， Sidlow R ， Hellmann MD . Immune-related adverse events associated with immune checkpoint blockade [J ] . N Engl J Med ， 2018 ， 378 （ 2 ）： 158 - 168 .

Barroso-Sousa R ， Ott PA ， Hodi FS ， et al . Endocrine dysfunction induced by immune checkpoint inhibitors：practical recommendations for diagnosis and clinical management [J ] . Cancer ， 2018 ， 124 （ 6 ）： 1111 - 1121 .

Kleffel S ， Posch C ， Barthel SR ， et al . Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth [J ] . Cell ， 2015 ， 162 （ 6 ）： 1242 - 1256 .

Liotti F ， Kumar N ， Prevete N ， et al . PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells [J ] . J Exp Clin Cancer Res ， 2021 ， 40 （ 1 ）： 22 .

June CH ， O'Connor RS ， Kawalekar OU ， et al . CAR T cell immunotherapy for human cancer [J ] . Science ， 2018 ， 359 （ 6382 ）： 1361 - 1365 .

Sterner RC ， Sterner RM . CAR-T cell therapy：current limitations and potential strategies [J ] . Blood Cancer J ， 2021 ， 11 ： 69 .

Min IM ， Shevlin E ， Vedvyas Y ， et al . CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors [J ] . Clin Cancer Res ， 2017 ， 23 （ 24 ）： 7569 - 7583 .

Vedvyas Y ， McCloskey JE ， Yang YP ， et al . Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy [J ] . Sci Rep ， 2019 ， 9 ： 10634 .

Jo Y ， Ali LA ， Shim JA ， et al . Innovative CAR-T cell therapy for solid tumor：current duel between CAR-T spear and tumor shield [J ] . Cancers ， 2020 ， 12 （ 8 ）： 2087 .

Blass E ， Ott PA . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines [J ] . Nat Rev Clin Oncol ， 2021 ， 18 （ 4 ）： 215 - 229 .

Yoo SK ， Song YS ， Lee EK ， et al . Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer [J ] . Nat Commun ， 2019 ， 10 ： 2764 .

Pozdeyev N ， Gay LM ， Sokol ES ， et al . Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers [J ] . Clin Cancer Res ， 2018 ， 24 （ 13 ）： 3059 - 3068 .

Landa I ， Ibrahimpasic T ， Boucai L ， et al . Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers [J ] . J Clin Invest ， 2016 ， 126 （ 3 ）： 1052 - 1066 .

Xu B ， Ghossein R . Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma [J ] . Endocr Pathol ， 2016 ， 27 （ 3 ）： 205 - 212 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Alterations of adenosine in tumor microenvironment and its impact on tumor treatment

An analysis of hot issues in immunotherapy for non-small cell lung cancer

Research advances in the interaction between tumor-associated macrophages and T cell subsets

Risk factors and prognosis of checkpoint inhibitor pneumonitis

Research progress in immunotherapy for autoimmune encephalitis

Related Author

Yang Quanjun

Han Leng

Bai Dingyuan

Zhou Yuxuan

Zhu Xinting

Zhang Jiayu

Guo Cheng

Jing Lingjie

Related Institution

Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Cancer Center，Renmin Hospital of Wuhan University

Department of Oncology， The First Affiliated Hospital of Shandong First Medical University

School of Clinical Medicine，Shandong Second Medical University

Department of Neurology，The Second People's Hospital of Hefei

⁰